Dr. Oh on a Biomarker Development Trial in mCRPC

William K. Oh, MD
Published: Thursday, Mar 20, 2014

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial in metastatic castrate-resistant prostate cancer (mCRPC). Oh was an author on the trial presented at the 2014 Genitourinary Cancers Symposium.

Satraplatin is a next-generation platinum chemotherapy drug that will not move forward in development. It is known that there is a subset of patients with advanced CRPC that respond to platinum chemotherapy, Oh says. Researchers are interested in determining this subset and are developing blood- and tissue-based biomarkers.

In prostate cancer, there are several subsets of patients that will respond to various treatments, but platinum is an important class of drug for neuroendocrine-type differentiated cancers.

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial in metastatic castrate-resistant prostate cancer (mCRPC). Oh was an author on the trial presented at the 2014 Genitourinary Cancers Symposium.

Satraplatin is a next-generation platinum chemotherapy drug that will not move forward in development. It is known that there is a subset of patients with advanced CRPC that respond to platinum chemotherapy, Oh says. Researchers are interested in determining this subset and are developing blood- and tissue-based biomarkers.

In prostate cancer, there are several subsets of patients that will respond to various treatments, but platinum is an important class of drug for neuroendocrine-type differentiated cancers.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x